Rezolute (RZLT) Total Non-Current Liabilities (2011 - 2026)
Rezolute recorded quarterly Total Non-Current Liabilities of $8.1 million in Q1 2026, down 20.01% quarter-over-quarter from $10.1 million in Q4 2025, and down 30.55% year-over-year from $11.7 million in Q1 2025.
Rezolute's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $8.1 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 30.55% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $8.1 million (down 30.55% YoY), while the FY2025 annual figure was $12.9 million, up 14.46% from the prior year.
- Total Non-Current Liabilities came in at $8.1 million for Q1 2026 at Rezolute, down from $10.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $17.3 million in Q1 2022 to a low of $2.5 million in Q3 2022.
- A 5-year average of $9.8 million and a median of $10.0 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities sank 85.28% in 2022 and jumped 263.56% in 2023, its largest moves.
- Rezolute's Total Non-Current Liabilities stood at $8.5 million in 2022, then grew by 17.06% to $10.0 million in 2023, then climbed by 19.88% to $11.9 million in 2024, then retreated by 15.02% to $10.1 million in 2025, then declined by 20.01% to $8.1 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $8.1 million, $10.1 million, and $11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 8.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.12 Mn |
| Dec 31, 2025 | 10.15 Mn |
| Sep 30, 2025 | 11.01 Mn |
| Jun 30, 2025 | 12.90 Mn |
| Mar 31, 2025 | 11.69 Mn |
| Dec 31, 2024 | 11.94 Mn |
| Sep 30, 2024 | 9.52 Mn |
| Jun 30, 2024 | 11.27 Mn |
| Mar 31, 2024 | 16.42 Mn |
| Dec 31, 2023 | 9.96 Mn |
| Sep 30, 2023 | 9.01 Mn |
| Jun 30, 2023 | 7.14 Mn |
| Mar 31, 2023 | 6.44 Mn |
| Dec 31, 2022 | 8.51 Mn |
| Sep 30, 2022 | 2.48 Mn |
| Jun 30, 2022 | 2.54 Mn |
| Mar 31, 2022 | 17.27 Mn |
| Dec 31, 2021 | 20.76 Mn |
| Sep 30, 2021 | 16.83 Mn |
| Jun 30, 2021 | 16.12 Mn |
| Jun 30, 2020 | 3.60 Mn |
| Mar 31, 2020 | 4.36 Mn |
| Dec 31, 2019 | 5.83 Mn |
| Sep 30, 2019 | 5.87 Mn |
| Jun 30, 2019 | 2.12 Mn |
| Mar 31, 2019 | 10.81 Mn |
| Dec 31, 2018 | 10.24 Mn |
| Sep 30, 2018 | 173,270.00 |
| Jun 30, 2018 | 215,623.00 |
| Mar 31, 2018 | 237,404.00 |
| Dec 31, 2017 | 268,732.00 |
| Sep 30, 2017 | 299,176.00 |
| Jun 30, 2017 | 329,621.00 |
| Mar 31, 2017 | 314,655.00 |
| Dec 31, 2016 | 335,588.00 |
| Sep 30, 2016 | 367,813.00 |
| Jun 30, 2016 | 400,038.00 |
| Mar 31, 2016 | 431,341.00 |
| Dec 31, 2015 | 460,794.00 |
| Sep 30, 2015 | 453,586.00 |
| Jun 30, 2015 | 503,617.00 |
| Mar 31, 2015 | 553,445.00 |
| Dec 31, 2014 | 534,717.00 |
| Sep 30, 2014 | 354,763.00 |
| Jun 30, 2014 | 33,881.00 |
| Dec 31, 2011 | 54,958.00 |